Novogen is an emerging oncology-focused biotechnology company, based in Sydney.
The new corporate entity will enable Novogen to interact directly with the Chinese Food and Drug Administration (CFDA) for future clinical trials in China.
The agreement defines the key terms, with most of the work expected to be conducted in the first half of calendar 2018.
It is also expected that the Chinese entity will be a Wholly Foreign Owned Enterprise (WFOE), headquartered in Shanghai.
Novogen is developing GDC-0084, a novel targeted therapy that modulates the PI3K pathway to treat glioblastoma multiforme (GBM).
GBM is the most common and most aggressive form of brain cancer.
Licensed from Genentech in late 2016, GDC-0084 is anticipated to enter phase II clinical trials this year.
Novogen has several preclinical programs in active development, the largest of which is substantially funded by a CRC-P grant from the Australian Federal Government.
The partnership with Cedrus Investments will help Novogen to engage with researchers and investors to support the development of its current and future pipeline.